Janney Montgomery Scott reiterated their neutral rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note issued to investors on Friday morning.

A number of other research analysts have also recently weighed in on TSRO. Zacks Investment Research upgraded shares of TESARO from a sell rating to a hold rating in a research report on Friday, March 31st. Cowen and Company set a $145.00 price objective on shares of TESARO and gave the company a hold rating in a research report on Saturday, June 10th. Gabelli started coverage on shares of TESARO in a research report on Friday, July 7th. They set a buy rating and a $175.00 price objective on the stock. FBR & Co cut their price objective on shares of TESARO from $202.00 to $200.00 and set a mkt perform rating on the stock in a research report on Wednesday, May 10th. Finally, Robert W. Baird reiterated a neutral rating on shares of TESARO in a research report on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $173.74.

TESARO (TSRO) traded down 4.25% on Friday, hitting $120.81. 1,247,071 shares of the stock were exchanged. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The stock’s market cap is $6.51 billion. The company has a 50-day moving average of $146.21 and a 200-day moving average of $151.73.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. TESARO’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.22) EPS. On average, equities analysts predict that TESARO will post ($8.75) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “TESARO, Inc. (TSRO) Receives “Neutral” Rating from Janney Montgomery Scott” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/17/tesaro-inc-tsro-receives-neutral-rating-from-janney-montgomery-scott.html.

In other TESARO news, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 34.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after buying an additional 3,335,611 shares during the last quarter. Norges Bank purchased a new stake in TESARO during the fourth quarter valued at approximately $40,158,000. TIAA CREF Investment Management LLC raised its stake in TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock valued at $56,550,000 after buying an additional 230,353 shares during the last quarter. Bank of New York Mellon Corp raised its stake in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock valued at $103,954,000 after buying an additional 175,273 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock valued at $448,705,000 after buying an additional 103,759 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.